Ferhat CATAL, Mehmet Semih DEMİRTAS, Erdem TOPAL

A twelve-year-old female patient developing anaphylaxis during the initial phase of conventional immunotherapy: a case report

Allerjen spesifik immünoterapi, astım hastalarında ve alerjik rinit tedavisinde kullanılan bir tedavi yöntemidir. Alerjen spesifik immünoterapisinin uygulamasından sonra, lokal ve sistemik reaksiyonlar ortaya çıkabilmektedir. Olgumuz, alerjik rinokonjuktivit tanısı alan ve verilen medikal tedaviye rağmen şikayetleri kontrol altına alınamayan bir hastaydı ve konvansiyonel immünoterapi tedavisi başlanıldı. Konvansiyonel immünoterapinin başlangıç fazında yapılan subkutan enjeksiyondan yaklaşık on dakika sonra nefes darlığı öksürük ve vücudunda yaygın kaşıntı şikayeti başladı. Hastaya immünoterapiye bağlı anafilaksi tanısı konuldu. Bu olgu nedeniyle alerjik rinit ve astım tedavisinde etkin olarak kullanılan immünoterapi enjeksiyonuna bağlı şiddetli sistemik reaksiyonların (anaflaksi) görülebileceği bir kez daha vurgulamak istenildi

Konvansiyonel immünoterapinin başlangıç fazında anafilaksi gelişen on iki yaşında kız hasta: bir olgu sunumu

Allergen specific immunotherapy is administered toasthmatic patients and allergic rhinitis treatment. Local and systemic reactions can occur after administration of allergen specific immunotherapy. Our case was a patient with allergic rhinoconjunctivitis whose complaints could not be controlled by medical treatment and eventually subcutaneous immunotherapy was administered. Approximately ten minutes after subcutaneous injection during the initial phase of conventional immunotherapy, the patient developed shortness of breath, cough and pruritus and was diagnosed with anaphylaxis due to immunotherapy. We aim to emphasize that severe systemic reactions (anaphylaxis) can occur due to immunotherapy injections which are effectively used in the treatment of allergic rhinitis and asthma.

PDF

___

Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Fi-negold I. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011;127(Suppl1):S1-S55.
Greineder DK. Risk management in allergen immunotherapy. J Allergy Clin Immunol 1996;98(6 Pt 3):S330-S4
Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI. Immediate and delayed-onset systemic reactions after subcutaneous immunotherapy injections: ACA-AI/AAAAI surveillance study of subcutaneous immunotherapy: year 2. Ann Allergy Asthma Immunol 2011;107:426-31.
Mário Morais-Almeida, Cristina Arêde, Graça Sampaio, Luis Miguel Borrego. Ultrarush schedule of subcutaneous immunotherapy with modified allergen extracts is safe in paediatric age: Asia Pac Allergy 2016;6:35-42.
Pfaar O, Urry Z, Robinson DS, Sager A, Richards D, Hawrylowicz CM, Brautigam M, limek L. A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy. Allergy 2012;67:272-79.
Pfaar O, Robinson DS, Sager A, Emuzyte R. Immunotherapy with depigmented-polymerized mixed tree pollen extract: a clinical trial and responder analysis. Allergy 2010;65:1614- 21.
Hernandez N, Ibero M, Ridao M, Artigas R, Vinas M, Castillo MJ. Safety of specific immunotherapy using a depigmented and polymerised extract of Dermatophagoides pteronyssinus in children under five years of age. Allergol Immunopathol 2011;39:267-70.
Pfaar O, Sager A, Robinson DS. Safety and effect on reported symptoms of depigmented polymerized allergen immunotherapy: a retrospective study of 2927 paediatric patients. Pediatr Allergy Immunol 2015;26:280-86.
Tinkelman DG, Cole WQ 3rd, Tunno J. Immunotherapy: a one-year prospective study to evaluate risk factors of systemic reactions. J Allergy Clin Immunol 1995;95:8-14.
Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol 2006;117:169-75.
Betül Ayşe SİN. Allerjik Hastalıklarda İmmünoterapi. Turkiye Klinikleri J Allergy-Asthma 1999;1:42-52.